Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7217674

A fluorescent assay for complement activation.

L H Caporale·S S Gaber·W Kell·O Götze
View original source ↗Export metadata ↓

Abstract

We report here a rapid assay for the complement enzymes CVFBb, C4b2a and Cls. This assay involves the use of a peptide substrate that releases a fluorescent coumarin derivative (AMC) upon cleavage by the convertase. The substrate, BocLeuGlyArgAMC, was chosen because its sequence is similar to the carboxyl terminus of C3a, and identical to that of C5a. The Km of this substrate are about 125 microM for the C3/5 convertase CVFBb, 169 microM for C4b2a, and 140 microM for C1s.

Explore related subjects

Complement ActivationComplement C1Complement C2Complement C4CoumarinsElapid VenomsFluorescenceHydrolysisJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L H Caporale, S S Gaber, W Kell, O Götze. 1981. A fluorescent assay for complement activation.. https://pubmed.ncbi.nlm.nih.gov/7217674/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

[Activation of plasma cascade systems in sepsis: role of C1 inhibitors].

During sepsis the complement system, the contact activation system and the coagulation cascade are activated. Activation of these plasmatic cascades contributes to the development of multiple organ failure and the high mortality rate of severe sepsis and septic shock. C1-inhibitor is the main inhibitor of the classical pathway of the complement system (C1s and C1r), of the contact activation system (factor XIIa and kallikrein) and of the intrinsic pathway of coagulation (factor XIa). During sepsis, C1-inhibitor is proteolytically inactivated. The increase of inactivated C1-inhibitor in plasma correlates positively with mortality in septic patients. C1-inhibitor substitution has been shown to reduce the mortality in experimental animals with severe sepsis or septic shock. Only a few cases of C1-inhibitor substitution in patients with severe sepsis or septic shock have been reported. C1-inhibitor has been shown to attenuate the activation of the complement system and the contact activation system and to improve hypotension. Based on this convincing pathophysiological concept and the results of the animal studies, we initiated the "Bernese C1-inhibitor study", a randomised double-blind and placebo-controlled pilot study involving administration of C1-inhibitor to patients with severe sepsis or septic shock. If the results of this pilot study confirm the results of the reports mentioned above, they will serve as a base for larger multicentre studies.

Complement Activation↗
PubMed1999

The complement system: pathophysiology and clinical relevance.

In the present article we review selected aspects of the complement system as a major determinant of innate immunity. Besides a detailed description of the components of the complement system, its mode of action, cellular receptors and regulatory control mechanisms, we have focused on the role of the complement system in mutual defence strategies of invading viral pathogens and the host. Since a detrimental activation of the complement cascade is a critical element of several pathological conditions in diverse organs, we summarise the role of a deteriorated complement system in dermatology, nephrology, neurology and xenotransplantation.

Complement Activation↗